BioWorld

Aug. 1, 2008

BMS After ImClone; Offers $60 per Share for Erbitux Partner

On the heels of Roche Holdings AG's $44 billion offer for Genentech Inc., as potentially the biggest buyout bid in the industry, another big pharma has made a play for its biotech collaborator. (BioWorld Today) Read More

No New Trials Needed for Cadence's Acetavance

iPS Cells from ALS Patients May Help Research, Therapy

FDA Restrictions on ESAs Bring Wall Street Yawns

Genmab, GSK CLL Drug Sails Through Pivotal Test

NewCo News: Sierra Raises $21.5M to Boost its CNS Drug Delivery Mode

AtheroGenics Riding High in Positive Diabetes Trial

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...